The Emirates Drug Establishment (EDE) has activated a new regulatory mechanism aimed at ending monopolistic practices in the UAE’s medical product market, marking a significant shift in how pharmaceuticals are distributed across the country.
Introduced under the 2024 federal law governing medical products, pharmacists and pharmaceutical establishments, the measure requires pharmaceutical companies to appoint more than one authorised agent for each medical product marketed in the UAE.
Officials say the move is designed to strengthen pharmaceutical security, ensure stable medicine supplies and enhance national preparedness during emergencies.
Ending single-agent control
Under the new framework, companies can no longer depend on a single distributor for a specific product.
By mandating multiple authorised agents, the EDE aims to:
- Prevent supply disruptions
- Improve distribution efficiency
- Increase supply-chain flexibility
- Eliminate monopolistic control over essential medicines
The authority said the mechanism will widen treatment options and promote healthier competition among distributors, ultimately benefiting patients and healthcare providers.
Boosting investment and market sustainability
Beyond addressing monopolies, the initiative is expected to make the UAE pharmaceutical sector more attractive to investors.
Officials note that diversified distribution channels reduce operational risks and enhance long-term sustainability, a key pillar in building a resilient healthcare ecosystem.
The reform aligns with the UAE’s broader strategy to modernise regulatory systems and position the country as a regional hub for life sciences and pharmaceutical trade.
Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the EDE’s Board of Directors, said the initiative reflects the UAE’s public policy approach to developing a robust national pharmaceutical ecosystem.
He emphasised the authority’s commitment to:
- Diversifying supply chains
- Enhancing regulatory efficiency
- Creating a flexible legislative environment
- Protecting public health
Officials stress that the mechanism goes beyond market competition. It serves as a strategic safeguard to ensure uninterrupted access to medicines during global disruptions or health emergencies.
What it means for the healthcare sector
The activation of the mechanism signals a transition toward a more competitive, transparent and secure pharmaceutical market.
- For patients: Greater consistency in medicine availability
- For distributors: Increased competition and operational flexibility
- For investors: A stronger, more sustainable regulatory environment
As implementation of the 2024 federal law continues, further refinements are expected to shape the future of the UAE’s pharmaceutical supply chain and reinforce national health security.